|
Magyar Pszichiátriai Társaság |
|
EPA Academia Summer School 2013. |
Rendezvény kezdete: 2013.06.07. | Rendezvény vége: 2013.06.10. |
Helyszín: France, 67000 Strasbourg, 15 Avenue de la Liberte |
Applications for the 3rd EPA Summer School on "Comorbidity between mental and physical disorders" are now being accepted. This 3rd edition will take place 7-10 June 2013 in Strasbourg, France, under the auspices of the Secretary General of the Council of Europe, Mr Thorbjørn Jagland.
The EPA Summer School is tailored for psychiatrists and other medical specialists who are either trainees or within 2 years of completion of specialist training, and who are residing in Europe. The 25 best applicants will be selected by the Jury to attend the Summer School.
Deadline for applications: 28 February 2013. |
|
|
 |
|
Magyar Endokrinológiai és Anyagcsere Társaság |
|
XIV CAPRI CONFERENCE "Novel Mechanisms and clinical aspects of cardiovascular disorders |
Rendezvény kezdete: 2011.04.15. | Rendezvény vége: 2011.04.17. |
Szakterület(ek): Hipertónia, Kardiológia |
Tudományos információ: Aristea International |
Címe: Italy, 00198 Roma, Via Lima, 31 |
Tel: +39 06 845431 |
Fax: +39 06 84543700 |
E-mail: roma@aristea.com |
Szervező: Aristea International |
Munkahely neve: Aristea |
Címe: Italy, 00198 Roma, Via Lima, 31 |
Tel: +39 06 845431 |
Fax: +39 06 84543700 |
E-mail: roma@aristea.com |
Helyszín: www.capriconference.org, XIV CAPRI CONFERENCE "Novel Mechanisms and clinical aspects of cardiovascular disorders" |
The Capri Conference is an established and an international event where join together to develop and deal with the multiple and different discoveries that surround the Cardiovascular world.
This year our invited experts will discuss on various issues: from the management of Thromboembolism to the Atrial fibrillation, from new Antiplatelet Agents to Genetic aspects of Cardiomyopathies and to the latest guide line for the treatment of hypertension, heart and kidney.
The following are some of the Hot Topics:
• RAAS and metabolic syndrome
• Antialdosteronic therapy
• Lipids and cv events in the year 2011 – Residual risk
• New advances in the knowledge of renin
• Prevention/protection of MAU in hypertension
• BP targets in hypertension
• RAS and plaque stability
• RAS and vascular remodeling
• AT2 receptor agonists
• Prevention of CV disease in diabetes
• Prorenin/renin receptors
|
|
|
 |